Novavax (FRA:NVV1) Inventories, Work In Process: €7.5 Mil (As of Mar. 2026)


FRA:NVV1 Novavax Inc FRA:NVV1
50 GF Score
Price €8.02
GF Value €3.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Inventories, Work In Process?

Novavax FRA:NVV1 -3.53% 50 Inventories, Work In Process is €7.5 Mil as of Mar. 2026. GuruFocus rates FRA:NVV1 with a GF Score™ of 50/100 and a GF Value™ of €3.38 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Novavax's work in process for the quarter that ended in Mar. 2026 was €7.5 Mil.

Novavax Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Novavax's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Inventories, Work In Process Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 20.21 6.78 4.68 6.48

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.99 6.89 6.21 6.48 7.50
FRA:NVV1
50GF Score
Novavax Inc FRA:NVV1
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €7.5 Mil mean?
Novavax (FRA:NVV1) has a Inventories, Work In Process of €7.5 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Novavax and its competitors.
Is Novavax's Inventories, Work In Process too high?
Novavax's current Inventories, Work In Process is €7.5 Mil. Overall, Novavax has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Inventories, Work In Process compare to MPLT and COAG?
Novavax's Inventories, Work In Process of €7.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Novavax and its competitors. Novavax's current Inventories, Work In Process is €7.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (FRA:NVV1) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.38, compared to a current price of €8.02 — trading 137.3% above its estimated fair value. The current Inventories, Work In Process is €7.5 Mil. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Novavax (FRA:NVV1), the current Inventories, Work In Process is €7.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €8.02 is trading 137.3% above its estimated GF Value™ of €3.38. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • Inventories, Work In Process: €7.5 Mil
  • GF Value™: €3.38 vs. price of €8.02 (137.3% above fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score

Get the complete analysis for FRA:NVV1

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.02
Price
€3.38
GF Value